Supplemental material
Journal of Medical Economics
Volume 26, 2023 - Issue 1
Respiratory Medicine
Cost-effectiveness of tezepelumab in Canada for severe asthma
Mara Habasha AstraZeneca Canada, Mississauga, Canada
https://orcid.org/0000-0002-2160-3957View further author information
https://orcid.org/0000-0002-2160-3957View further author information, , Irvin Mayersc Department of Medicine, University of Alberta, Edmonton, Canadahttps://orcid.org/0000-0003-3875-1961View further author information
https://orcid.org/0000-0003-3875-1961View further author information, , , , , Danny Gibsond AstraZeneca PLC, Cambridge, United Kingdomhttps://orcid.org/0009-0004-5979-1756View further author information
https://orcid.org/0009-0004-5979-1756View further author information & Adrian P. Turnera AstraZeneca Canada, Mississauga, CanadaCorrespondence[email protected]
https://orcid.org/0009-0004-6926-2188View further author information
https://orcid.org/0009-0004-6926-2188View further author information show all